Non-anaplastic peripheral T cell lymphoma in children and adolescents-an international review of 143 cases

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F16%3A10324714" target="_blank" >RIV/00064203:_____/16:10324714 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/16:00092588 RIV/00216208:11130/16:10324714 RIV/65269705:_____/16:00066091

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s00277-016-2722-y" target="_blank" >http://dx.doi.org/10.1007/s00277-016-2722-y</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00277-016-2722-y" target="_blank" >10.1007/s00277-016-2722-y</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Non-anaplastic peripheral T cell lymphoma in children and adolescents-an international review of 143 cases

Popis výsledku v původním jazyce

Peripheral T cell lymphomas (PTCL) are rare in children and adolescents, and data about outcome and treatment results are scarce. The present study is a joint, international, retrospective analysis of 143 reported cases of non-anaplastic PTCL in patients < 19 years of age, with a focus on treatment and outcome features. One hundred forty-three patients, between 0.3 and 18.7 years old, diagnosed between 2000 and 2015 were included in the study. PTCL not otherwise specified was the largest subgroup, followed by extranodal NK/T cell lymphoma, hepatosplenic T cell lymphoma (HS TCL), and subcutaneous panniculitis-like T cell lymphoma (SP TCL). Probability of overall survival (pOS) at 5 years for the whole group was 0.56 +/- 0.05, and probability of event-free survival was (pEFS) 0.45 +/- 0.05. Patients with SP TCL had a good outcome with 5-year pOS of 0.78 +/- 0.1 while patients with HS TCL were reported with 5-year pOS of only 0.13 +/- 0.12. Twenty-five percent of the patients were reported to have a pre-existing condition, and this group had a dismal outcome with 5-year pOS of 0.29 +/- 0.09. The distribution of non-anaplastic PTCL subtypes in pediatric and adolescent patients differs from what is reported in adult patients. Overall outcome depends on the subtype with some doing better than others. Pre-existing conditions are frequent and associated with poor outcomes. There is a clear need for subtype-based treatment recommendations for children and adolescents with PTCL.

Název v anglickém jazyce

Non-anaplastic peripheral T cell lymphoma in children and adolescents-an international review of 143 cases

Popis výsledku anglicky

Peripheral T cell lymphomas (PTCL) are rare in children and adolescents, and data about outcome and treatment results are scarce. The present study is a joint, international, retrospective analysis of 143 reported cases of non-anaplastic PTCL in patients < 19 years of age, with a focus on treatment and outcome features. One hundred forty-three patients, between 0.3 and 18.7 years old, diagnosed between 2000 and 2015 were included in the study. PTCL not otherwise specified was the largest subgroup, followed by extranodal NK/T cell lymphoma, hepatosplenic T cell lymphoma (HS TCL), and subcutaneous panniculitis-like T cell lymphoma (SP TCL). Probability of overall survival (pOS) at 5 years for the whole group was 0.56 +/- 0.05, and probability of event-free survival was (pEFS) 0.45 +/- 0.05. Patients with SP TCL had a good outcome with 5-year pOS of 0.78 +/- 0.1 while patients with HS TCL were reported with 5-year pOS of only 0.13 +/- 0.12. Twenty-five percent of the patients were reported to have a pre-existing condition, and this group had a dismal outcome with 5-year pOS of 0.29 +/- 0.09. The distribution of non-anaplastic PTCL subtypes in pediatric and adolescent patients differs from what is reported in adult patients. Overall outcome depends on the subtype with some doing better than others. Pre-existing conditions are frequent and associated with poor outcomes. There is a clear need for subtype-based treatment recommendations for children and adolescents with PTCL.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Annals of Hematology

ISSN

0939-5555

e-ISSN

—

Svazek periodika

95

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

11

Strana od-do

1295-1305

Kód UT WoS článku

000379189100010

EID výsledku v databázi Scopus

2-s2.0-84976260191